Open Beta
TREN
MetriLume
TREN

US marketsABUS

SEC-sourced researchBeta

ABUS

Arbutus Biopharma Corp

Company comparison ↗

Data passport

CIK
0001447028
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Oct 5, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 6,171,000.0000 USD; December 2025: 14,083,000.0000 USD14.1M USD0 USD0December 2024December 2025
ABUS · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20246,171,000.0000Mar 23, 2026
December 202514,083,000.0000Mar 23, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202514,083,000.0000-33,501,000.0000-39,637,000.000094,618,000.000018,042,000.0000Mar 23, 2026
December 20246,171,000.0000-69,920,000.0000-64,850,000.0000131,707,000.000034,341,000.0000Mar 23, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

56/100
Profitability0
Growth100
Balance sheet81
Cash generation0
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$14.08MJan 1, 2025 – Dec 31, 2025Mar 23, 202610-K
Previous period revenueRevenues$6.17MJan 1, 2024 – Dec 31, 2024Mar 23, 202610-K
Net incomeNetIncomeLoss-$33.5MJan 1, 2025 – Dec 31, 2025Mar 23, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$39.64MJan 1, 2025 – Dec 31, 2025Mar 23, 202610-K
Total assetsAssets$94.62MDec 31, 2025Mar 23, 202610-K
Total liabilitiesLiabilities$18.04MDec 31, 2025Mar 23, 202610-K

New filings

Explore methodology ↗